HC Wainwright Has Pessimistic Outlook of AQST Q3 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Aquestive Therapeutics in a report released on Tuesday, February 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.16) per share for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.61) EPS.

A number of other analysts have also recently commented on AQST. Wall Street Zen cut shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. JMP Securities lifted their price target on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a report on Thursday, October 9th. Zacks Research upgraded Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Finally, Lake Street Capital set a $6.00 target price on Aquestive Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $8.50.

Aquestive Therapeutics Trading Down 4.0%

NASDAQ:AQST opened at $3.84 on Thursday. The stock has a market capitalization of $468.48 million, a PE ratio of -5.41 and a beta of 1.65. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $7.55. The firm has a fifty day simple moving average of $5.09 and a 200 day simple moving average of $5.20.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $12.81 million during the quarter, compared to analysts’ expectations of $12.94 million.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of large investors have recently made changes to their positions in AQST. Commonwealth Equity Services LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at about $5,918,000. Pale Fire Capital SE raised its stake in Aquestive Therapeutics by 25.5% in the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock worth $5,549,000 after purchasing an additional 340,767 shares in the last quarter. Sio Capital Management LLC raised its stake in Aquestive Therapeutics by 141.9% in the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock worth $3,136,000 after purchasing an additional 555,860 shares in the last quarter. Diametric Capital LP bought a new position in shares of Aquestive Therapeutics during the second quarter worth approximately $547,000. Finally, Everstar Asset Management LLC raised its position in shares of Aquestive Therapeutics by 119.5% in the second quarter. Everstar Asset Management LLC now owns 658,607 shares of the company’s stock valued at $2,180,000 after buying an additional 358,607 shares in the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.